Financials
Financial year 2025
MJ Pharma from Vorselaar, company number BE0755612578, closed financial year 2025 with a result of € 61,088 after tax. For that financial year MJ Pharma recorded a gross margin of € 68,664 and equity of € 277,228. Compared with financial year 2024, the result moved from € 105,472 to € 61,088. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 277,228
▼ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 61,088
▼ 42% vs 2024
Profit after tax over the fiscal year.
€ 3,835
▼ 66% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 105,472 paid out
More than the year’s profit went to the shareholders; reserves fell.
Debts at end 2025
€ 239,157
▼ 17% vs 2024
€ 48,287 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 30
▼ € 9,446 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 18,179
▲ € 16,962 vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 69,137 | € 68,845 | € 68,702 | € 68,664 | |
| Profit after taxes | € 69,977 | € 95,662 | € 105,472 | € 61,088 | ▼ 42% |
| Equity | € 120,477 | € 216,139 | € 321,611 | € 277,228 | ▼ 14% |
| Total debts | € 426,854 | € 369,343 | € 297,683 | € 257,520 | ▼ 13% |
| Cash | € 24,238 | € 12,149 | € 11,367 | € 3,835 | ▼ 66% |
| Retained profit | € 117,977 | € 213,639 | € 319,111 | € 274,728 | ▼ 14% |
| Dividend | € 0 | € 0 | € 0 | € 105,472 | |
| Bank debt | € 380,401 | € 333,915 | € 286,836 | € 239,157 | ▼ 17% |
| Balance sheet total | € 547,331 | € 585,482 | € 619,294 | € 534,747 | ▼ 14% |
Key figures of MJ Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MJ Pharma?
What happened at MJ Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 61,088 (▼ 42% vs 2024). Source: NBB ↗
- New establishment in Vorselaar. KBO
- Julie Schyvens became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 69,977 profit in 2022 to € 61,088 profit in 2025.
Paid € 80,454 in corporate taxes since 2022.
Best year ever: 2024, with € 105,472 profit.
Paid out € 105,472 in dividends to the owners in total.
Management
Behind MJ Pharma is Julie Schyvens. It owns 50% of VITAPO itself.
Directors
According to the 2025 annual accounts
since 2020
Establishments
Establishment units
Physical locations of this company
Kerkstraat 18
2290 Vorselaar
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0755.612.578
- VAT number
- BE 0755.612.578
- Registered office
- Kerkstraat 18, 2290 Vorselaar
- Names & denominations
- MJ Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 October 2020
- Peppol
- Active · Active since 21 Nov 2024
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van hoofdkantoren
Overige zakelijke dienstverlening, neg